Literature DB >> 30047835

Delineating the active site architecture of G9a lysine methyltransferase through substrate and inhibitor binding mode analysis: a molecular dynamics study.

M Ramya Chandar Charles1, Hsing-Pang Hsieh2, Mohane Selvaraj Coumar1.   

Abstract

Mono- and di-methylation of the H3K9 residue in the histone tail by G9a lysine methyltransferase is associated with transcriptional suppression of genes. Here, we use molecular dynamics simulation and free energy calculations of five different modified/mutated G9a substrate peptides to elucidate the rationale behind the substrate binding to G9a. We also investigated the binding energy contribution based architecture of the active site of G9a to understand substrate and inhibitor binding. Wild-type peptide (H3K9) shows better binding affinity than mono- and di-methylated lysine (K9) and other modified peptides (K9A and R8A). Arg8 of the substrate peptide is crucial for determining the degree of conformational freedom/stability of the wild-type substrate peptide, as well as binding to G9a. Our results also suggest that the G9a active site is segregated into energy rich and low regions, and the energy rich region alone is used by the inhibitors for binding. These insights into the active site architecture should be taken into consideration in virtual screening experiments designed to discover novel inhibitors for G9a. In particular, compounds that could interact with the six residues of G9a - Asp1074, Asp1083, Leu1086, Asp1088, Tyr1154 and Phe1158 - should be preferentially tested in G9a inhibition biological assays. Communicated by Ramaswamy H. Sarma.

Entities:  

Keywords:  G9a inhibitors; G9a lysine methyltransferase; Histone methylation; epigenetics; molecular dynamics simulation

Mesh:

Substances:

Year:  2018        PMID: 30047835     DOI: 10.1080/07391102.2018.1491422

Source DB:  PubMed          Journal:  J Biomol Struct Dyn        ISSN: 0739-1102


  3 in total

1.  Mimicking H3 Substrate Arginine in the Design of G9a Lysine Methyltransferase Inhibitors for Cancer Therapy: A Computational Study for Structure-Based Drug Design.

Authors:  M Ramya Chandar Charles; Mu-Chun Li; Hsing-Pang Hsieh; Mohane Selvaraj Coumar
Journal:  ACS Omega       Date:  2021-02-22

Review 2.  EHMT2/G9a as an Epigenetic Target in Pediatric and Adult Brain Tumors.

Authors:  Barbara Kunzler Souza; Natalia Hogetop Freire; Mariane Jaeger; Caroline Brunetto de Farias; Algemir L Brunetto; André T Brunetto; Rafael Roesler
Journal:  Int J Mol Sci       Date:  2021-10-19       Impact factor: 5.923

3.  Structure-Based Virtual Screening and in vitro and in vivo Analyses Revealed Potent Methyltransferase G9a Inhibitors as Prospective Anti-Alzheimer's Agents.

Authors:  Aina Bellver-Sanchis; Bhanwar Singh Choudhary; Júlia Companys-Alemany; Pedro A Ávila-López; Antón Leandro Martínez Rodríguez; Jose Manuel Brea Floriani; Ruchi Malik; Mercè Pallàs; Belén Pérez; Christian Griñán-Ferré
Journal:  ChemMedChem       Date:  2022-05-19       Impact factor: 3.540

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.